Korea University-Moderna mRNA Hantavirus Vaccine Stalls as Funding Shortfall Blocks Clinical Trials
核心洞察
Korea University's Vaccine Innovation Center and Moderna have developed an mRNA-based hantavirus (搜索) vaccine that demonstrated protective efficacy in mouse studies, but human clinical trials remain stalled for over a year due to funding constraints.
The project requires 10-20 billion won for GMP facility production to advance to clinical trials, far exceeding the team's available budget despite initial support from Hyundai's 10 billion won donation.
Hantavirus (搜索) affects 300-500 people annually in Korea and is classified by WHO as a potential "Disease X" pandemic pathogen, highlighting the urgent need for improved vaccines beyond the limited Hantavax (搜索) currently available.
Korea University's Vaccine Innovation Center and U.S. biotech giant Moderna have achieved a significant preclinical milestone in developing an mRNA-based hantavirus (搜索) vaccine, but the promising research has stalled for over a year as funding shortfalls prevent advancement to human clinical trials.
The collaboration, formalized through a research and development agreement in September 2023 under Moderna's mRNA Access initiative, has successfully demonstrated protective efficacy against hantavirus (搜索) infection in mouse studies. A research team led by Professor Park Man-sung of Korea University College of Medicine's Department of Microbiology confirmed these positive results in February 2025, marking a crucial step toward addressing a significant unmet medical need.
Funding Crisis Threatens Progress
Despite the scientific breakthrough, the project faces a critical funding gap that threatens its continuation. Producing clinical trial vaccines at Good Manufacturing Practice (GMP) facilities requires between 10 billion won (€6.5 million) and 20 billion won (€13 million), far exceeding the team's available budget. The consortium, comprising Korea University's Vaccine Innovation Center, EyeGene (搜索), and Medici Bio (搜索), is currently awaiting final selection results for the Korea Disease Control and Prevention Agency (搜索)'s "Priority Infectious Disease Pandemic Preparedness Rapid Development Technology Establishment Project."
If selected for this national initiative, the consortium would receive up to 1.5 billion won annually over two years, with the goal of establishing systems capable of developing vaccines within 200 days of a pandemic outbreak. However, this funding level remains insufficient for the substantial costs required for clinical development.
Addressing a Critical Medical Need
Hantavirus (搜索) causes hemorrhagic fever with renal syndrome (搜索), characterized by high fever, bleeding, and kidney damage. The pathogen was first discovered in 1976 by the late Korea University Emeritus Professor Lee Ho-wang, leading to the commercialization of Korea's first domestically developed new drug, the hemorrhagic fever vaccine "Hantavax (搜索)," in 1990.
However, the current vaccine has significant limitations. Manufactured by inactivating the virus strain prevalent in Korea at that time, Hantavax (搜索) offers limited long-term immune efficacy and cannot prevent hantavirus pulmonary syndrome (搜索) (HPS) prevalent in the United States and elsewhere. In Korea, approximately 300-500 people are infected annually, mainly military personnel in their 20s and 30s.
The World Health Organization has classified hantavirus (搜索) infection as one of the candidates for "Disease X," a potential future pandemic pathogen. The Korea Disease Control and Prevention Agency (搜索) has designated hantavirus as one of nine priority pathogens for future pandemic preparedness, underscoring the strategic importance of developing improved vaccines.
Collaborative Research Framework
Under the partnership agreement, Korea University's Vaccine Innovation Center provided Moderna with hantavirus antigen (搜索) sequence information, while Moderna supplied the corresponding mRNA material for antigen expression studies. The collaboration builds on Moderna's mRNA platform technology that proved successful during the COVID-19 (搜索) pandemic.
VIC-K director Heejin Cheong stated that the project was designed to "continue the legacy" of Professor Lee Ho-wang's pioneering work. Moderna chief medical officer Francesca Ceddia emphasized that the partnership would "strengthen mRNA vaccine research and development capabilities in Korea."
Declining Investment Climate
The funding challenges reflect broader trends in infectious disease research investment. Government R&D spending on infectious diseases, which had surged to 661 billion won immediately after COVID-19 (搜索), dropped to 434.3 billion won in 2024. The share of infectious disease R&D in the total R&D budget also declined from a peak of 2.2% in 2022 to 1.6% in 2024.
Private investment efforts have similarly stalled due to limited commercial prospects. As a "neglected infectious disease" occurring primarily in rural areas and military bases, hantavirus (搜索) vaccines face small market sizes and uncertain revenue projections, providing little incentive for companies to bear the substantial clinical trial costs.
Global Market Potential
Despite current funding constraints, researchers see significant potential for international expansion. "If we succeed in developing an mRNA hantavirus (搜索) vaccine, there is significant potential to enter markets in the United States and China," a Vaccine Innovation Center official noted. With hantavirus infections likely to increase due to climate change, demand for more effective vaccines is expected to grow globally.
The project has been supported in part by a 10 billion won personal donation from Hyundai Motor Group (搜索) Honorary Chairman Chung Mong-koo, who previously contributed 100 billion won to establish the Vaccine Innovation Center at Korea University. Korea University Medical Center has also invested approximately 50 billion won of its own funds to build state-of-the-art research facilities, though its annual operating budget remains limited at about 350 million won.
Field researchers point to the government's "reactive support" approach as a fundamental barrier to sustained infectious disease vaccine development. They argue that comprehensive government support is essential for vaccines with low profitability, citing successful examples from the United States and Germany, where substantial public investment enabled rapid mRNA vaccine development during the pandemic.